Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
The latest available 13F covers holdings as of Jun 30, 2026 (Q2 2026) and was filed Aug 14, 2026. Quarter-end snapshot, not a live trade.
Disclosed 13F value
$42.3B
sum of reported positions
Reported positions
227
Changes vs prior quarter
244
33 new · 48 exited
Filings on record
9
Q2 2026, Q1 2026, Q4 2025, Q3 2025, Q2 2025, Q1 2025, Q4 2024, Q3 2024, Q2 2024
Across 284 measured positions in 8 quarters, the typical new or larger position finished −1.8 pts against the S&P 500 and 47% finished ahead of it. For scale, across all 501 funds with a result: −2.2 pts typical, 44% ahead.
Measured on each position this fund reported as new or larger, from the first close after the filing became public, against the S&P 500, 90 days later. Sales are not scored. History, not a forecast; it shows what the stocks did, not what the fund knew.
Total value of the 13F each quarter. It moves with prices as well as with what the fund bought or sold, so a rise is not necessarily a purchase.
Comparison uses this manager's immediately preceding 13F-HR. Puts and calls are separate lines. Share counts drive classification; reported value also moves with price.Methodology
Change in the reported value against the quarter before.
Weights are within the disclosed 13F portfolio, for the ten largest lines.
| Q1 2026 | Q2 2026 | |
|---|---|---|
| Reported value | $28.2B | $42.3B |
| Positions | 242 | 227 |
| Biggest line | — | Apple 7% |
| 5.56M |
| $1.99B |
| 4.7% |
| 2.84M | $1.65B | 3.9% |
| 1.22M | $1.41B | 3.3% |
| 493K | $1.12B | 2.7% |
| 2.36M | $1.02B | 2.4% |
| 984K | $950M | 2.2% |
| 6.71M | $937M | 2.2% |
| 2.93M | $883M | 2.1% |
| 2.13M | $805M | 1.9% |
| 3.06M | $781M | 1.8% |
| 1.92M | $685M | 1.6% |
| 1.57M | $617M | 1.5% |
| 1.73M | $611M | 1.4% |
| 1.67M | $570M | 1.3% |
| 939K | $529M | 1.3% |
| 793K | $507M | 1.2% |
| 1.56M | $451M | 1.1% |
| 2.53M | $430M | 1.0% |
| 1.15M | $418M | 1.0% |
| 538K | $411M | 1.0% |
| 2.49M | $404M | 1.0% |
| 1.97M | $368M | 0.9% |
Jade Biosciences (JBIO)
1.85M shares
Datadog (DDOG)
157K shares
RadNet, Inc. (RDNT)
734K → 623K shares (−15%)
Mineralys Therapeutics (MLYS)
1.5M → 1.42M shares (−5%)
Axon Enterprise (AXON)
24K → 67K shares (+179%)
Definium Therapeutics (DFTX)
777K shares
Tesla (TSLA)
258K → 87K shares (−66%)
JPMorgan Chase (JPM)
113K → 107K shares (−5%)
Trip.Com Group (TCOM)
991K → 878K shares (−11%)
Taysha Gene Therapies (TSHA)
5.65M → 5.12M shares (−10%)
Relay Therapeutics (RLAY)
1.79M shares
Affirm Holdings (AFRM)
379K → 405K shares (+7%)
Centene Corporation (CNC)
746K → 472K shares (−37%)
Aflac (AFL)
375K → 250K shares (−33%)
Affiliated Managers Group (AMG)
87K → 85K shares (−2%)
Agilent Technologies (A)
161K → 216K shares (+34%)
Dyne Therapeutics (DYN)
1.36M → 1.29M shares (−5%)
ON Semiconductor (ON)
192K → 299K shares (+56%)
Stoke Therapeutics (STOK)
1.13M → 834K shares (−26%)
Bioage Labs (BIOA)
1.13M → 1.07M shares (−5%)
NXP Semiconductors (NXPI)
58K → 92K shares (+58%)
Mda Space (MDA)
624K shares
Cigna (CI)
116K → 88K shares (−24%)
Littelfuse (LFUS)
59K → 52K shares (−11%)
Guardant Health (GH)
173K → 159K shares (−8%)
